Stay updated with breaking news from Solid Tumors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MCLA-145 monotherapy and in combination with pembrolizumab rapid oral session presentation: June 2, 2024, 11:30 a.m.-1:00 p.m. CT MCLA-129 in NSCLC with c-MET exon 14 skipping mutations poster presentation:
- 60% response rate observed among 10 evaluable patients - Favorable safety profile in 26 patients enrolled as of the abstract cutoff date, with no significant overlapping toxicities observed -
OPTIMIZE-1 study results showed confirmed ORR of 40.4%, unconfirmed ORR of 50.9% and DCR of 79% in 57 evaluable patients with chemotherapy-naïve mPDACThe encouraging duration of response (median 12.5 months)
– Results from pivotal Phase 2b ReNeu trialofmirdametinib in patients with NF1-PN to be presented in an oral presentation –
Press release - 360iResearch - Hazardous Waste Management Market worth $1,515.01 million by 2030, growing at a CAGR of 14.90% - Exclusive Report by 360iResearch - published on openPR.com